Nintedanib: all 136 studies that test it
Page 2 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Ph II Nintedanib vs. Ifosfamide in Soft Tissue SarcomaTerminatedNCT02808247Phase 2
- Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and PharmacodynamicsCompletedNCT02619162Phase 1
- Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and NeckStatus unknownNCT02558387Phase 2
- Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung CancerCompletedNCT02531737Phase 2
- Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaCompletedNCT02308553Phase 1/2
- BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial CarcinomaStatus unknownNCT02278978Phase 2
- Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung CancerCompletedNCT02225405Phase 1
- Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy SubjectsCompletedNCT02182258Phase 1
- A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCompletedNCT02182232Phase 1
- Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNCT02182219Phase 1
- An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid TumoursCompletedNCT02182206Phase 1
- Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male VolunteersCompletedNCT02182193Phase 1
- Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male VolunteersCompletedNCT02182154Phase 1
- An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02182141Phase 1
- A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid TumoursCompletedNCT02182128Phase 1
- Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung CancerCompletedNCT02182102Phase 1
- Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male VolunteersCompletedNCT02182076Phase 1
- A Study With BIBF 1120 in Patients With Hormone Refractory Prostate CancerCompletedNCT02182063Phase 2
- Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung CancerCompletedNCT02182050Phase 2
- A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based ChemotherapyWithdrawnNCT02152059Phase 2
- ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix CancerCompletedNCT02009579Phase 2
- To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid TumoursCompletedNCT01951846Phase 1
- Nintedanib(BIBF1120) in Thyroid CancerCompletedNCT01788982Phase 2
- An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)CompletedNCT01684111Phase 1
- An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)CompletedNCT01683682Phase 1
- NOA-12: BIBF1120 and R-RT in GlioblastomaTerminatedNCT01666600Phase 1/2
- Phase II Study of Docetaxel +/- Nintedanib in Breast CancerCompletedNCT01658462Phase 2
- Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian CancerCompletedNCT01610869Phase 2
- Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian CancerCompletedNCT01583322Phase 2
- Doxorubicin + BIBF 1120 in Patients for Ovarian CancerTerminatedNCT01485874Phase 1
- BIBF 1120 as Second Line Treatment for Small Cell Lung CancerCompletedNCT01441297Phase 2
- TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)CompletedNCT01362361Phase 2
- BIBF 1120 and RAD001 in Solid Tumors - Phase ICompletedNCT01349296Phase 1
- BIBF 1120 in Recurrent Glioblastoma MultiformeCompletedNCT01251484Phase 2
- A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal CancerCompletedNCT00801294Phase 2
- Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid TumorsCompletedNCT00730821Phase 1